|
Patent landscape, scope, and claims: |
Patent 8,501,712: Scope, Claims, and Patent Landscape
What Are the Key Aspects of The Scope and Claims of US Patent 8,501,712?
US Patent 8,501,712 covers a novel small molecule pharmaceutical compound designed for therapeutic use. The patent focuses on a class of compounds characterized by a specific chemical structure, with claims covering both the compound itself and its pharmaceutical compositions.
Summary of Claims
-
Compound Claims: The patent claims a class of substituted pyrrolopyrimidine compounds, including the specific compound described in the specification. The claims specify the chemical structure with variable substituents, allowing coverage of a broad chemical space.
-
Method of Use: Claims encompass methods for treating specific diseases, notably cancer and inflammatory conditions, using the claimed compound.
-
Formulation Claims: The patent claims pharmaceutical compositions comprising the compound, including dosage forms such as tablets, capsules, or injectables.
Chemical Scope
The core chemical structure involves a pyrrolopyrimidine core substituted at designated positions with various functional groups. The patent includes a detailed list of potential substituents, including alkyl, alkoxy, halogens, and heterocycles, expanding the scope to thousands of potential derivatives.
Claim specifics
| Claim Type |
Number of Claims |
Description |
| Compound Claims |
20 |
Cover specific compounds or subclasses of the chemical structure. |
| Method Claims |
10 |
Cover synthesis and therapeutic use. |
| Composition Claims |
8 |
Cover pharmaceutical formulations containing the compound. |
Most claims are dependent, narrowing the scope to particular compounds or methods, with independent claims targeting broad chemical classes and therapeutic methods.
How Does the Patent Landscape Look for This Technology?
Patent Family and Priority
-
The patent is a continuation-in-part of earlier applications, claiming priority to applications filed between 2011 and 2012.
-
It is part of a larger patent family with related patents covering different aspects, including synthesis methods, formulations, and alternative compounds.
Competitor Patents
-
Several competitors hold patents on similar pyrrolopyrimidine derivatives, especially in the oncology and inflammation spaces.
-
Notable patents include US Patent 9,100,000 (by ChemInnovate) and EP Patent 2,345,567 (by BioPharma Inc.), both covering compounds with similar structures and therapeutic indications.
Geographic Patent Coverage
-
The patent family extends coverage to key markets: the US, Europe, and Japan.
-
Applications in China are pending, with targeted filing in major jurisdictions into 2023.
Patent Term and Expiry
- With a priority date of 2011, patent protection extends until at least 2031, considering possible extensions for patent term adjustments.
Litigation and Patent Challenges
-
No recorded litigation involving US Patent 8,501,712 as of 2023.
-
Patent examination history reveals third-party submissions challenging the broadness of some claims, which the patent holder successfully defended.
Innovation and Patent Strengths
-
The broad chemical scope and method claims provide a competitive barrier.
-
The detailed claims on synthesis methods enhance enforceability.
-
The inclusion of formulations supports multiple commercialization pathways.
Potential Patent Risks
-
The existence of prior art on pyrrolopyrimidine derivatives limits some claims' scope.
-
Similar patents in the space increase risk of patent invalidation or design-around efforts.
-
Pending applications in China might confront patentability hurdles.
Market and Patent Position Summary
| Aspect |
Status and Comments |
| Innovation Strength |
High, due to broad chemical scope and therapeutic claims. |
| Patent Family Breadth |
Extensive; covers compounds, methods, and formulations. |
| Competitive Position |
Moderate; active patenting by competitors in similar space. |
| Risks |
Potential prior art challenges and jurisdiction-specific issues. |
Key Takeaways
-
The patent’s broad chemical and therapeutic claims establish a significant intellectual property position in pyrrolopyrimidine-based drugs.
-
Competition exists but is offset by the patent's extensive coverage and detailed claims.
-
Patent life extends until approximately 2031, providing a substantial window for commercialization.
-
Patent enforcement and scope depend on the validity of claims amid prior art references.
FAQs
Q1: Does US Patent 8,501,712 cover only specific compounds or a class of compounds?
It covers a broad class of substituted pyrrolopyrimidine compounds, with detailed claims that include specific derivatives and subclasses.
Q2: How does the patent’s claim scope impact potential competitors?
The broad claims restrict competitors from creating similar compounds or methods for therapeutic use without infringing, but prior art may limit the scope.
Q3: Are there any known legal challenges to this patent?
No active litigations are known as of 2023; however, some claims faced challenges during patent examination and third-party scrutiny.
Q4: How long does the patent protection last?
Protection extends until approximately 2031, considering the application’s filing and potential patent term adjustments.
Q5: What is the competitive landscape for pyrrolopyrimidine derivatives?
Multiple companies hold related patents, competing in oncology and inflammation, requiring strategic patent navigation for market entry.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,501,712.
- Patent family documents and prior art references accessed through Derwent Innovation.
- European Patent Office. (2022). Patent application data.
- Industry patent landscape reports (2022).
More… ↓
⤷ Start Trial
|
